Piper Sandler Lowers IO Biotech Outlook as Company Pursues Strategic Alternatives
Piper Sandler reduced its rating on IO Biotech from Overweight to Neutral and cut the price target to $0.50 from $3.00 after the company announced a strategic review. The move follows concerns about the company’s cash runway despite positive five-year follow-up data for its IO102-IO103 vaccine program and recent leadership changes.